

Amendments to the Claims

1. (Cancelled)
2. (Cancelled)
3. (Currently Amended) A compound according to ~~Claim 1~~Claim 24 wherein X₁ is CH and X₂ is ~~selected~~ CH.
4. (Currently Amended) A compound according to ~~Claim 1~~Claim 24 wherein X₁ is CH and X₂ is ~~selected~~ N.
5. (Currently Amended) A compound according to ~~Claim 1~~Claim 24 wherein X₁ is N, and X₂ is CH.
6. (Currently Amended) A compound according to ~~Claim 1~~Claim 24 wherein X₁ is N, and X₂ is N.
7. (Cancelled)
8. (Cancelled)
9. (Currently Amended) A compound according to ~~Claim 2~~Claim 25 wherein X₁ is CH and X₂ is ~~selected~~ CH.
10. (Currently Amended) A compound according to ~~Claim 2~~Claim 25 wherein X₁ is CH and X₂ is ~~selected~~ N.
11. (Currently Amended) A compound according to ~~Claim 2~~Claim 25 wherein X₁ is N, and X₂ is CH.
12. (Currently Amended) A compound according to ~~Claim 2~~Claim 25 wherein X₁ is N, and X₂ is N.
13. (Cancelled)

14. (Cancelled)
15. (Cancelled)
16. (Cancelled)

17. (Currently Amended) A compound selected from the group consisting of:

4-{5-[(3-Methyl-butylamino)-methyl]-indol-1-ylmethyl}-benzamide,
4-{5-[(2-Thiophen-2-yl-ethylamino)-methyl]-indol-1-ylmethyl}-benzamide,
4-{5-[(3,3-Dimethyl-butylamino)-methyl]-indol-1-ylmethyl}-benzamide,
4-{5-[(2-Thiophen-2-yl-ethylamino)-methyl]-2,3-dihydro-indol-1-ylmethyl}-benzamide,
4-{5-[(3-Methyl-butylamino)-methyl]-2,3-dihydro-indol-1-ylmethyl}-benzamide,
4-{5-[(3,3-Dimethyl-butylamino)-methyl]-2,3-dihydro-indol-1-ylmethyl}-benzamide,
4-(5-Hexylaminomethyl-indol-1-ylmethyl)-benzamide,
4-{5-[(3-Phenyl-propylamino)-methyl]-indol-1-ylmethyl}-benzamide,
4-(5-{[2-(2-Fluoro-phenyl)-ethylamino]-methyl}-indol-1-ylmethyl)-benzamide,
4-{5-[(2-Hydroxy-ethylamino)-methyl]-indol-1-ylmethyl}-benzamide,
4-(5-{[2-(4-Methoxy-phenyl)-ethylamino]-methyl}-indol-1-ylmethyl)-benzamide,
4-{5-[(2-Chloro-6-fluoro-benzylamino)-methyl]-indol-1-ylmethyl}-benzamide,
4-{5-[(2-Pyridin-3-yl-ethylamino)-methyl]-indol-1-ylmethyl}-benzamide,
4-(5-{[2-(2-Ethoxy-phenyl)-ethylamino]-methyl}-indol-1-ylmethyl)-benzamide,
4-(5-{[2-(Tetrahydro-pyran-4-yl)-ethylamino]-methyl}-indol-1-ylmethyl)-benzamide,
4-{5-[(2-Cyclohex-1-enyl-ethylamino)-methyl]-indol-1-ylmethyl}-benzamide,
4-(5-{[2-(3-Fluoro-phenyl)-ethylamino]-methyl}-indol-1-ylmethyl)-benzamide,
4-{5-[(2-Ethyl-butylamino)-methyl]-indol-1-ylmethyl}-benzamide,
1-{4-[(3-Methyl-butylamino)-methyl]-benzyl}-2,3-dihydro-1H-indole-5-carboxylic acid amide,
1-{4-[(3-Methyl-butylamino)-methyl]-benzyl}-1H-indole-5-carboxylic acid amide,
or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer and diastereomeric mixture or solvate thereof.

18. (Currently Amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound of ~~formula I or II or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer or diastereomeric mixture thereof~~ Claim 24 in association with a carrier, diluent and/or excipient.

18. (Cancelled)

19. (Cancelled)


20. (Cancelled)

21. (Cancelled)

22. (Cancelled)

23. (Cancelled)

24. (New) A compound of formula (I)



(I)

wherein:


p is 0, 1, or 2;

y is 0, 1, or 2; and z is 0, 1, or 2;

X_1 is CH_2 , CH , or N ; to form a indolinyl, indolyl, or benzimidazole ring respectively and including applicable double bonds and/or hydrogen atoms;

X_2 is CH or N ;

R^1 and R^2 are independently selected from hydrogen, methyl, ethyl, propyl, isopropyl, 2-methylpentyl, t-butyl, cyclopropyl, phenyl,




each of which is optionally substituted with a group selected from the group consisting of halogen, C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₁-C₈ thioalkyl, C₁-C₈ alkylamino, phenyl, C₁-C₈ alkylsubstituted phenyl, C₄-C₈ heterocycle or C₁-C₄ alkyl heterocycle;

R³ and R^{3'} are each hydrogen;

R⁴ and R⁵ are each independently selected from fluoro, chloro, bromo, methoxy, ethoxy, methyl, ethyl, isopropyl, trifluoromethyl, phenyl and benzyl; wherein each R⁴ and R⁵ is attached to its respective ring only at carbon atoms; wherein m is 1 or 2; and n is 1, 2, or 3; R⁶ and R⁷ are each independently selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl and phenyl;

or a compound selected from the group 4-{5-[(2-Hydroxy-ethylamino)-methyl]-indol-1-ylmethyl}-benzamide; 4-(5-[(2-(4-Methoxy-phenyl)-ethylamino]-methyl)-indol-1-ylmethyl]-benzamide; 4-{5-[(2-Pyridin-3-yl-ethylamino)-methyl]-indol-1-ylmethyl}-benzamide; 4-(5-[(2-(2-Ethoxy-phenyl)-ethylamino]-methyl)-indol-1-ylmethyl]-benzamide; and 4-{5-[(2-Cyclohex-1-enyl-ethylamino)-methyl]-indol-1-ylmethyl}-benzamide; or a pharmaceutically acceptable salt or solvate thereof.

25. (New) A compound of formula II



II


wherein p is 0, 1, or 2;

y is 0, 1, or 2; and z is 0, 1, or 2;

X₁ is CH₂, CH, or N; to form a indolinyl, indolyl, or benzimidazole ring respectively and including applicable double bonds and/or hydrogen atoms;

X₂ is CH or N;

R¹ and R² are independently selected from hydrogen, methyl, ethyl, propyl, isopropyl, 2-methylpentyl, t-butyl, cyclopropyl, phenyl,



each of which is optionally substituted with a group selected from the group consisting of halogen, C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₁-C₈ thioalkyl, C₁-C₈ alkylamino, phenyl, C₁-C₈ alkylsubstituted phenyl, C₄-C₈ heterocycle or C₁-C₄ alkyl heterocycle;

R³ and R^{3'} are each hydrogen;

R⁴ and R⁵ are each independently selected from fluoro, chloro, bromo, methoxy, ethoxy, methyl, ethyl, isopropyl, trifluoromethyl, phenyl and benzyl; wherein each R⁴ and R⁵ is attached to its respective ring only at carbon atoms; wherein m is 1 or 2; and n is 1, 2, or 3;

R⁶ and R⁷ are each independently selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl and phenyl;
or a pharmaceutically acceptable salt or solvate thereof.

26. (New) A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 25 in association with a carrier, diluent and/or excipient.